Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Effect of Including Important Clinical Variables on Accuracy of the Lung Allocation Score for Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.

Lehr CJ, Skeans M, Dasenbrook EC, Fink A, Fernandez G, Faro A, Valapour M.

Am J Respir Crit Care Med. 2019 Jun 14. doi: 10.1164/rccm.201902-0252OC. [Epub ahead of print]

PMID:
31199166
2.

Mortality in Adults with Cystic Fibrosis Requiring Mechanical Ventilation. Cross-Sectional Analysis of Nationwide Events.

Siuba M, Attaway A, Zein J, Wang X, Han X, Strausbaugh S, Jacono F, Dasenbrook EC.

Ann Am Thorac Soc. 2019 Aug;16(8):1017-1023. doi: 10.1513/AnnalsATS.201804-268OC.

PMID:
31026405
3.

Eradication of persistent methicillin-resistant Staphylococcus aureus infection in cystic fibrosis.

Dezube R, Jennings MT, Rykiel M, Diener-West M, Boyle MP, Chmiel JF, Dasenbrook EC.

J Cyst Fibros. 2019 May;18(3):357-363. doi: 10.1016/j.jcf.2018.07.005. Epub 2018 Aug 18.

PMID:
30131297
4.

Cystic fibrosis patient registries: A valuable source for clinical research.

Dasenbrook EC, Sawicki GS.

J Cyst Fibros. 2018 Jul;17(4):433-440. doi: 10.1016/j.jcf.2018.03.001. Epub 2018 Mar 16. Review.

PMID:
29555479
5.

Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations.

West NE, Beckett VV, Jain R, Sanders DB, Nick JA, Heltshe SL, Dasenbrook EC, VanDevanter DR, Solomon GM, Goss CH, Flume PA; STOP investigators.

J Cyst Fibros. 2017 Sep;16(5):600-606. doi: 10.1016/j.jcf.2017.04.003. Epub 2017 Apr 29.

6.

Risk factors for persistent methicillin-resistant Staphylococcus aureus infection in cystic fibrosis.

Jennings MT, Dasenbrook EC, Lechtzin N, Boyle MP, Merlo CA.

J Cyst Fibros. 2017 Nov;16(6):681-686. doi: 10.1016/j.jcf.2017.04.010. Epub 2017 Apr 23.

PMID:
28446387
7.

Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis.

VanDevanter DR, Heltshe SL, Spahr J, Beckett VV, Daines CL, Dasenbrook EC, Gibson RL, Raksha J, Sanders DB, Goss CH, Flume PA; STOP Study Group.

J Cyst Fibros. 2017 Sep;16(5):607-615. doi: 10.1016/j.jcf.2017.04.004. Epub 2017 Apr 21.

8.

Preliminary comparison of normalized T1 and non-contrast perfusion MRI assessments of regional lung disease in cystic fibrosis patients.

Donnola SB, Dasenbrook EC, Weaver D, Lu L, Gupta K, Prabhakaran A, Yu X, Chmiel JF, McBennett K, Konstan MW, Drumm ML, Flask CA.

J Cyst Fibros. 2017 Mar;16(2):283-290. doi: 10.1016/j.jcf.2015.11.009. Epub 2015 Dec 22.

9.

Impact of lung allocation score on survival in cystic fibrosis lung transplant recipients.

Braun AT, Dasenbrook EC, Shah AS, Orens JB, Merlo CA.

J Heart Lung Transplant. 2015 Nov;34(11):1436-41. doi: 10.1016/j.healun.2015.05.020. Epub 2015 Jun 11.

10.

Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes.

Dasenbrook EC, Konstan MW, VanDevanter DR.

J Cyst Fibros. 2015 May;14(3):370-5. doi: 10.1016/j.jcf.2014.11.005. Epub 2014 Dec 11.

11.

Antibiotic management of lung infections in cystic fibrosis. II. Nontuberculous mycobacteria, anaerobic bacteria, and fungi.

Chmiel JF, Aksamit TR, Chotirmall SH, Dasenbrook EC, Elborn JS, LiPuma JJ, Ranganathan SC, Waters VJ, Ratjen FA.

Ann Am Thorac Soc. 2014 Oct;11(8):1298-306. doi: 10.1513/AnnalsATS.201405-203AS. Review.

12.

Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections.

Chmiel JF, Aksamit TR, Chotirmall SH, Dasenbrook EC, Elborn JS, LiPuma JJ, Ranganathan SC, Waters VJ, Ratjen FA.

Ann Am Thorac Soc. 2014 Sep;11(7):1120-9. doi: 10.1513/AnnalsATS.201402-050AS. Review.

13.
14.

Normalized T1 magnetic resonance imaging for assessment of regional lung function in adult cystic fibrosis patients--a cross-sectional study.

Dasenbrook EC, Lu L, Donnola S, Weaver DE, Gulani V, Jakob PM, Konstan MW, Flask CA.

PLoS One. 2013 Sep 25;8(9):e73286. doi: 10.1371/journal.pone.0073286. eCollection 2013.

15.

Isoflurane and ketamine anesthesia have different effects on ventilatory pattern variability in rats.

Chung A, Fishman M, Dasenbrook EC, Loparo KA, Dick TE, Jacono FJ.

Respir Physiol Neurobiol. 2013 Feb 1;185(3):659-64. doi: 10.1016/j.resp.2012.12.001. Epub 2012 Dec 14.

16.

Inhaled hypertonic saline in infants and young children with cystic fibrosis.

Dasenbrook EC, Konstan MW.

JAMA. 2012 Jun 6;307(21):2316-7. doi: 10.1001/jama.2012.5853. No abstract available.

17.

Update on methicillin-resistant Staphylococcus aureus in cystic fibrosis.

Dasenbrook EC.

Curr Opin Pulm Med. 2011 Nov;17(6):437-41. doi: 10.1097/MCP.0b013e32834b95ed. Review.

PMID:
21918450
18.

Cystic fibrosis and survival in patients with advanced lung disease.

Dasenbrook EC.

BMJ. 2011 Mar 7;342:d726. doi: 10.1136/bmj.d726. No abstract available.

PMID:
21382942
19.

Higher PEEP in patients with acute lung injury: a systematic review and meta-analysis.

Dasenbrook EC, Needham DM, Brower RG, Fan E.

Respir Care. 2011 May;56(5):568-75. doi: 10.4187/respcare.01011. Epub 2011 Jan 27. Review.

20.

Emergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland, Ohio.

Endimiani A, Blackford M, Dasenbrook EC, Reed MD, Bajaksouszian S, Hujer AM, Rudin SD, Hujer KM, Perreten V, Rice LB, Jacobs MR, Konstan MW, Bonomo RA.

Antimicrob Agents Chemother. 2011 Apr;55(4):1684-92. doi: 10.1128/AAC.01308-10. Epub 2011 Jan 24.

21.

Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis.

Dasenbrook EC, Checkley W, Merlo CA, Konstan MW, Lechtzin N, Boyle MP.

JAMA. 2010 Jun 16;303(23):2386-92. doi: 10.1001/jama.2010.791.

PMID:
20551409
22.

Prevalence and risk factors for recovery of filamentous fungi in individuals with cystic fibrosis.

Sudfeld CR, Dasenbrook EC, Merz WG, Carroll KC, Boyle MP.

J Cyst Fibros. 2010 Mar;9(2):110-6. doi: 10.1016/j.jcf.2009.11.010. Epub 2009 Dec 31.

23.

Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis.

Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E.

JAMA. 2008 Nov 26;300(20):2407-16. doi: 10.1001/jama.2008.717. Review. Erratum in: JAMA. 2009 Mar 11;301(10):1024.

24.

Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis.

Dasenbrook EC, Merlo CA, Diener-West M, Lechtzin N, Boyle MP.

Am J Respir Crit Care Med. 2008 Oct 15;178(8):814-21. doi: 10.1164/rccm.200802-327OC. Epub 2008 Jul 31.

PMID:
18669817

Supplemental Content

Loading ...
Support Center